Generative AI-Supported Personalized Education Compared With Printed Material for Adults With Hypertension (GenAI-HYPER)
18 augusti 2026 uppdaterad av: Akdeniz University
The Effect of Generative Artificial Intelligence-Supported Personalized Education Compared With Printed Material on Hypertension Knowledge and Medication Adherence in Adults With Hypertension
This study evaluates whether generative artificial intelligence-supported personalized education can improve hypertension knowledge and medication adherence in adults with hypertension compared with standard printed educational material.
A total of 88 adults with hypertension are included in the study.
Participants are assigned to either an intervention group or a control group.
The control group receives a printed hypertension education booklet.
The intervention group receives personalized educational content prepared using generative artificial intelligence based on individual characteristics and needs, together with weekly WhatsApp or SMS messages, voice messages, and brief telephone follow-up.
The intervention lasts four weeks, and final assessments are performed in the fifth week.
Hypertension knowledge, medication adherence self-efficacy, and blood pressure are assessed before and after the intervention.
It is expected that personalized education will improve hypertension knowledge and medication adherence compared with printed education.
Studieöversikt
Status
Aktiv, inte rekryterande
Betingelser
Studietyp
Interventionell
Inskrivning (Faktisk)
88
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Antalya
-
Antalya, Antalya, Turkiet (Türkiye), 07070
- Akdeniz University Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Voluntary agreement to participate in the study
- Diagnosis of hypertension
- Use of antihypertensive medication for at least 6 months
- Medication adherence self-efficacy score of 26 or lower
- Age 18 years or older
- Ability to read and write in Turkish
- General health status adequate for communication
- Ability to read SMS messages and use WhatsApp
Exclusion Criteria:
- Withdrawal from the study after enrollment
- Inability to be reached by telephone during the follow-up period
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: control group
Participants in this arm receive standard hypertension education and a printed hypertension education booklet.
Baseline assessments and blood pressure measurements are performed in the first week.
In the fifth week, post-intervention assessments and blood pressure measurements are repeated.
|
Participants receive standard hypertension education including medication-related information and a printed hypertension education booklet developed based on expert recommendations.
|
|
Experimentell: intervention group
Participants in this arm receive generative artificial intelligence-supported personalized hypertension education based on their individual characteristics, needs, baseline information, and the standardized hypertension education content.
The intervention is delivered over four weeks through weekly WhatsApp or SMS messages and voice messages.
Brief structured telephone follow-up is conducted during the first and fourth weeks.
In the fifth week, post-intervention assessments and blood pressure measurements are performed.
|
Participants receive personalized hypertension education generated using generative artificial intelligence based on individual characteristics, needs, baseline information, and standardized hypertension education content.
The intervention is delivered over four weeks through weekly WhatsApp or SMS messages and voice messages.
Brief structured telephone follow-up is provided in the first and fourth weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mean Change From Baseline in Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF) Total Score at Week 5
Tidsram: Baseline and Week 5
|
Medication adherence self-efficacy will be assessed using the 13-item Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF).
Each item is scored from 1 (not at all sure) to 4 (very sure), resulting in a total score ranging from 13 to 52.
Higher scores indicate greater self-efficacy for adhering to antihypertensive medication.
The change in total score from baseline to Week 5 will be evaluated.
|
Baseline and Week 5
|
|
Mean Change From Baseline in Hypertension Knowledge-Level Scale (HK-LS) Total Score at Week 5
Tidsram: Baseline and Week 5
|
Hypertension knowledge will be assessed using the 22-item Hypertension Knowledge-Level Scale (HK-LS).
The scale includes six domains: definition, medical treatment, medication adherence, lifestyle, diet, and complications.
Responses are recorded as true, false, or do not know, and each correct response receives 1 point.
Higher scores indicate greater hypertension knowledge, and a score of 16 or above indicates a high level of hypertension knowledge.
The change in total score from baseline to Week 5 will be evaluated.
|
Baseline and Week 5
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mean Change From Baseline in Systolic Blood Pressure at Week 5
Tidsram: Baseline and Week 5
|
Systolic blood pressure will be measured in mmHg at baseline and Week 5.
The change in systolic blood pressure from baseline to Week 5 will be evaluated.
|
Baseline and Week 5
|
|
Mean Change From Baseline in Diastolic Blood Pressure at Week 5
Tidsram: Baseline and Week 5
|
Diastolic blood pressure will be measured in mmHg at baseline and Week 5.
The change in diastolic blood pressure from baseline to Week 5 will be evaluated.
|
Baseline and Week 5
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Yasemin DEMİR AVCI, PhD, Akdeniz University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 juni 2026
Primärt slutförande (Beräknad)
20 december 2026
Avslutad studie (Beräknad)
20 december 2026
Studieregistreringsdatum
Först inskickad
18 augusti 2026
Först inskickad som uppfyllde QC-kriterierna
18 augusti 2026
Första postat (Faktisk)
20 augusti 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
20 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
18 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- AKDENIZU-TBAEK-711
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .